Key statistics
On Friday, Autolus Therapeutics PLC (6A3A:STU) closed at 3.38, 72.45% above the 52 week low of 1.96 set on Oct 04, 2023.
52-week range
Open | 3.32 |
---|---|
High | 3.38 |
Low | 3.32 |
Bid | 3.48 |
Offer | 3.66 |
Previous close | 3.38 |
Average volume | 0.00 |
---|---|
Shares outstanding | 266.09m |
Free float | 8.82m |
P/E (TTM) | -- |
Market cap | 1.05bn USD |
EPS (TTM) | -1.16 USD |
Data delayed at least 15 minutes, as of Aug 30 2024.
More ▼
- Autolus Therapeutics Presents Clinical Data Update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024
- Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates
- Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
- Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
- Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO
- Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
- Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call
- Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
- Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
- Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)
More ▼